INTRODUCTION AND OBJECTIVES: Persistently elevated prostate-specific antigen (PSA) after radical prostatectomy (RP) is associated with recurrent disease and poor prognosis. Predictors that may be associated with persistent PSA need to be evaluated in order to better counsel patients and gauge postoperative outcomes. We sought to assess independent clinical and pathologic predictors of persistently elevated PSA after RP in a contemporary cohort.
METHODS: We identified a cohort of patients with non-metastatic prostate cancer who underwent RP from 2006-2016 at the Cleveland Clinic Foundation. Independent predictors of persistently elevated PSA were identified using chi-square and multivariate logistic regression analyses, accounting for patient demographic and clinicopathologic factors. Persistently elevated PSA was defined as !0.1 six weeks after RP.
RESULTS: Of a total 2,710 patients undergoing RP, 158 patients had persistently elevated PSA after surgery (5.8%). On multivariate analysis, clinicopathologic factors associated with persistently elevated PSA included initial PSA >20 ng/mL (OR 2.8; p<0.01), extraprostatic extension (OR 3.3; p<0.01), seminal vesicle invasion (OR 1.6; p¼0.048), positive surgical margin (OR 2.0; p<0.01), lymph node involvement (OR 2.5; p<0.01), and pathologic Gleason score !8 (OR 4.5; p<0.01).
CONCLUSIONS: With persistently elevated PSA after RP recognized as a marker of continued disease progression, clinicopathologic factors that predicted persistently elevated PSA were characterized in a contemporary cohort. These results highlight factors that can assist with determination of necessity for adjuvant therapy and help with better patient counseling prior to and following prostatectomy.
Source of Funding: None

MP64-20 PATHOLOGICAL UPGRADING AND UPSTAGING AT RADICAL PROSTATECTOMY IN JAMAICAN MEN WITH LOW RISK PROSTATE CANCER
Belinda Morrison*, Gareth Reid, Richard Mayhew, William Aiken, Barrie Hanchard, Kingston, Jamaica INTRODUCTION AND OBJECTIVES: Several studies suggest race-based health disparities in men with low-risk prostate cancer (PCa), with African-American males having poorer oncological outcomes. We sought to determine the predictors of pathological upgrading and upstaging in a cohort of black Jamaican males with low-risk PCa who underwent radical prostatectomy (RP) between 2000 and 2015.
METHODS: We studied 141 men who met National Comprehensive Cancer Network criteria for low-risk PCa and underwent RP at the University Hospital of the West Indies, Kingston, Jamaica. All men had a minimum of a 12 core trans-rectal ultrasound-guided biopsy. Preoperative clinical and final pathological data were obtained. Data were summarized as means and standard deviations or percentages as appropriate. Bivariate analyses such as independent samples t tests and chi square tables were conducted and logistic regression models were estimated to predict upgrading (> Gleason 6) and upstaging (! pT3).
RESULTS: Mean age was 59.5 AE 7.8 years with mean PSA of 6.6 AE 2 ng/ml. A total of 48.3% of men were upgraded and 30.8% were upstaged. Bivariate analyses indicated that PSA levels (p¼0.008) and percentage of cancer found on biopsy (p¼0.002) were associated with upgrading. Clinical T stage (p¼0.020), number of positive cores found (p¼0.024) and the percentage of cancer found on biopsy (p¼0.004) were significantly associated with upstaging. The odds of upgrading increased with increased PSA levels (OR ¼ 1.40; p¼ 0.021) or increased percentages of cancer found (OR ¼ 8.27; p ¼ 0.002). The odds of upstaging increased with increased percentages of cancer found (OR ¼ 3.62; p ¼ 0.039).
CONCLUSIONS: Jamaican males with low-risk PCa have high rates of poor pathological outcomes. Percentage cancer found on biopsy is significantly associated with upgrading and upstaging. These findings should be taken into consideration when discussing treatment options for these patients. 
Source of Funding: None
INTRODUCTION AND OBJECTIVES: Intravesical Bacillus
Calmette-Gu erin (BCG) immunotherapy has been used to treat nonmuscle invasive bladder cancer (BC) for nearly 40 years but its underlying mechanism remains largely unknown. It is generally believed that BCG adheres to integrin ?5?1 in the urothelial lining by interacting with fibronectin, then triggers an immune response cascade. Extracellular vesicles (EVs), small membrane-bound vesicles, act as immune modulators by transferring molecular cargos to recipient cells. We hypothesize that EVs derived from BC cells play key roles in mediating BCG-induced anti-tumor host immune responses, and the patient derived EVs may serve as predictive biomarkers that can differentiate BCG responders from non-responders.
METHODS: BC cell lines, human T24 and murine MB49, and immortalized bladder SV-HUC cells were treated with 1-4x106 CFU/ml live BCG. After 12-72 hours, secreted EVs were isolated by serial ultracentrifugation and analyzed by Nanoparticle Tracking Analysis. Cell lysate and total RNA was collected for immuno-molecular profiling by quantitative PCR and Western blotting analyses. The alterations in EV secretion, gene and protein expression, and molecules from BC derived EVs in response to BCG were compared. Urinary EVs were collected and purified before and after BCG patients' 1st and 3rd BCG instillations and EV secretion profiles were compared.
RESULTS: In response to BCG, SV-HUC cells showed decreased EV secretion and their immuno-molecules were significantly reduced compared with EVs from naïve SV-HUC cells. In contrast, in BC cells the EV secretion rate was significantly induced by BCG as well as the expression of the key molecules in modulating immune response, such as MHC and co-stimulatory molecules at gene and protein levels. Critically, we found that BC cells, but not SV-HUC cells, released immuno-molecules containing EVs in response to BCG. Importantly, we found that urinary EV numbers were increased significantly after the 3rd BCG instillation in BCG responders, but not in BCGnon-responders in a pilot study.
CONCLUSIONS: We conclude that BCG treatment resulted in increased EV release from BC cells as well as in increased EVs in urine e852 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Sunday, May 14, 2017 
